Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 30/5/2020
SIETES contiene 93014 citas

 
 
 1 a 20 de 22 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Zhu H, Bateman BT, Gray KJ, Hernandez-Diaz S, Mogun H, Starub L, Huybrechts KF. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. BMJ 2020;369:20 de mayo. [Ref.ID 103628]
3. Cita con resumen
Menezes de Pádua CA, Uter W, Schnuch A. Contact allergy to topical drugs: prevalence in a clinical setting and estimation of frequency at the population level. Pharmacoepidemiol Drug Saf 2007;16:377-84. [Ref.ID 79963]
4. Cita con resumen
Anónimo. WHO not to include tenofovir in new essential drug list. Scrip 2005;3071:19. [Ref.ID 74336]
5. Cita con resumen
Anónimo. Topical sertaconazole (Ertaczo) - another azole for Tinea pedis. Med Lett Drugs Ther 2004;46:50-2. [Ref.ID 70844]
6.
Frattarelli DAC, Reed M D, Giacoia GP, Aranda JV. Antifungals in systemic neonatal candidiasis. Drugs 2004;64:949-68. [Ref.ID 69863]
7. Cita con resumen
Horrobin DF. Are large clinical trials in rapidly lethal diseases usually unethical?. Lancet 2003;361:695-7. [Ref.ID 65125]
8.
Levine AM. Evaluation and management of HIV-infected women. Ann Intern Med 2002;136:228-42. [Ref.ID 60540]
9. Cita con resumen
Anónimo. Precios de referencia: Orden de 13 de julio de 2000 (B.O.E. 25-7-00). Inf Ter Sist Nac Salud 2000;24:129-33. [Ref.ID 53084]
10. Cita con resumen
Sobel JD. Use of antifungal drugs in pregnancy: a focus on safety. Drug Saf 2000;23:77-85. [Ref.ID 51860]
11. Cita con resumen
Venkatakrishnan K. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80. [Ref.ID 49421]
12.Tiene citas relacionadas
Hart R, Bell-Syer SEM, Crawford F, Young P, Russell I, Torgerson DJ. Fungal infections of skin and nails of feet. Authors of meta-analysis defend their view. BMJ 1999;319:1071. [Ref.ID 47266]
13.
Niewerth M, Korting HC. Management of onychomycoses. Drugs 1999;58:283-96. [Ref.ID 46285]
14.
Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, Marroum P. In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin Pharmacol Ther 1999;66:9-15. [Ref.ID 46241]
15.Tiene citas relacionadas Cita con resumen
Hart R, Bell-Syer SEM, Crawford F, Torgerson DJ, Young P, Russell I. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ 1999;319:79-82. [Ref.ID 45931]
16. Cita con resumen
Czeizel AE, Tóth M, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999;10:437-40. [Ref.ID 45191]
17.
Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430. [Ref.ID 44173]
18. Cita con resumen
Anónimo. Topical butenafine for tinea pedis. Med Lett Drugs Ther 1997;39:63-4. [Ref.ID 34144]
19.
Peli L, Naldi L. Micosi superficiali: breve guida alla diagnosi e al trattamento. Informazioni sui Farmaci 1996;20:95-8. [Ref.ID 29471]
20.
Thomas DHV, Noyce P R. The interface between self medication and the NHS. BMJ 1996;312:688-91. [Ref.ID 26174]
Seleccionar todas
 
 1 a 20 de 22 siguiente >>